

Special Issue

Pathology and Genetics of Glioblastoma

Message from the Guest Editor

Glioblastomas (GBMs) are the most common primary brain tumors of adults. They show aggressive behavior and a poor prognosis, and despite intensive research on molecular targets, there is still no curative therapy. In the current 2021 WHO Classification of CNS tumors, novel genetic and epigenetic aspects are highlighted, contributing to GBM initiation and progression. The most common genetic alterations in GBMs are TERT mutations as well as EGFR amplifications and CDKN2A/B deletions. Furthermore, GBMs show aberrant DNA-methylation landscapes altering numerous biological pathways. This leads to an intimate relationship of GBM cells with the microenvironment, supporting tumor growth. Therefore, it is necessary to understand genetic and epigenetic mechanisms occurring in GBMs in order to develop advanced therapy strategies. This Special Issue invites contributions (original research articles and reviews) that highlight our enhanced understanding of the genomic and epigenomic landscape of GBMs to better understand the pathology underlying glioblastomas, opening up new ways in glioblastoma therapy.

Guest Editor

Dr. Theo Kraus

Institute of Pathology, University Hospital Salzburg, Paracelsus Medical University, Müllner Hauptstr. 48, A-5020 Salzburg, Austria

Deadline for manuscript submissions

closed (10 November 2023)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/163969

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)